Investment analysts at Cann began coverage on shares of Agios Pharmaceuticals Inc. (NASDAQ:AGIO) in a note issued to investors on Monday, The Fly reports. The firm set a “market perform” rating on the biopharmaceutical company’s stock.
Several other equities analysts also recently commented on AGIO. Cowen and Company reiterated a “buy” rating on shares of Agios Pharmaceuticals in a research report on Thursday, November 3rd. Leerink Swann reiterated a “market perform” rating on shares of Agios Pharmaceuticals in a research report on Friday, November 4th. Zacks Investment Research downgraded Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, October 5th. Goldman Sachs Group Inc. reiterated a “neutral” rating and issued a $46.00 target price on shares of Agios Pharmaceuticals in a research report on Wednesday, August 10th. Finally, Credit Suisse Group AG reiterated a “buy” rating on shares of Agios Pharmaceuticals in a research report on Monday, November 21st. Six research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $61.94.
Agios Pharmaceuticals (NASDAQ:AGIO) traded down 4.35% during trading on Monday, hitting $60.90. The stock had a trading volume of 379,545 shares. Agios Pharmaceuticals has a one year low of $33.50 and a one year high of $71.49. The firm’s market capitalization is $2.56 billion. The stock has a 50 day moving average of $54.47 and a 200 day moving average of $48.35.
Agios Pharmaceuticals (NASDAQ:AGIO) last posted its earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($1.63) EPS for the quarter, missing the consensus estimate of ($1.52) by $0.11. The firm earned $8.98 million during the quarter, compared to the consensus estimate of $7.82 million. Agios Pharmaceuticals had a negative net margin of 341.56% and a negative return on equity of 53.39%. Agios Pharmaceuticals’s revenue for the quarter was up 63.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.07) earnings per share. Equities research analysts expect that Agios Pharmaceuticals will post ($5.15) earnings per share for the current fiscal year.
In related news, Director Lewis Clayton Jr. Cantley sold 2,504 shares of the firm’s stock in a transaction that occurred on Thursday, October 27th. The stock was sold at an average price of $48.94, for a total transaction of $122,545.76. Following the completion of the sale, the director now owns 108,405 shares of the company’s stock, valued at $5,305,340.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Scott Biller sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 20th. The stock was sold at an average price of $50.00, for a total value of $250,000.00. Following the sale, the insider now directly owns 48,270 shares of the company’s stock, valued at approximately $2,413,500. The disclosure for this sale can be found here. Corporate insiders own 10.55% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in the company. AlpInvest Partners B.V. acquired a new stake in Agios Pharmaceuticals during the second quarter valued at approximately $1,257,000. Emerald Acquisition Ltd. purchased a new stake in shares of Agios Pharmaceuticals during the second quarter worth approximately $319,000. BlackRock Advisors LLC boosted its stake in shares of Agios Pharmaceuticals by 1,942.6% in the second quarter. BlackRock Advisors LLC now owns 253,023 shares of the biopharmaceutical company’s stock worth $10,600,000 after buying an additional 240,636 shares during the period. Capital Fund Management S.A. purchased a new stake in shares of Agios Pharmaceuticals during the second quarter worth approximately $1,250,000. Finally, JPMorgan Chase & Co. boosted its stake in shares of Agios Pharmaceuticals by 425.5% in the second quarter. JPMorgan Chase & Co. now owns 30,882 shares of the biopharmaceutical company’s stock worth $1,294,000 after buying an additional 25,005 shares during the period. 89.27% of the stock is owned by institutional investors and hedge funds.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs), which are a subset of orphan genetic metabolic diseases. Its cancer product candidates are AG-221 and AG-120, which targets mutated isocitrate dehydrogenase 2 and 1, or IDH2 and IDH1, respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.